Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Drugs Affecting Neurotransmitter Release or Uptake

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Oxazole-4,5-dicarboxylate derivatives as multifunctional targets against oral cancer and <i>Streptococcus mutans</i> oral pathogens.

Future medicinal chemistry·2026

Same author

Renoprotective Mechanisms of SGLT2 Inhibitors: Integrating Clinical and Experimental Evidence from Inflammation to Fibrosis.

Recent advances in inflammation & allergy drug discovery·2026

Same author

Cervical Spine Movements With Single-Handed Versus Bimanual Cricoid Pressure Under Simulated Cervical Immobilization: A Randomized Controlled Trial.

Journal of neurosurgical anesthesiology·2026

Same author

Clinical Utility of Infrared Thermography in Pediatric Patients: A Systematic Review of Surgical and Nonsurgical Applications.

Journal of Indian Association of Pediatric Surgeons·2026

Same author

Innovations in Hemorrhage Management: Calcium Alginate, Celox, and Desmopressin as Next-generation Hemostatic Agents.

Cardiovascular & hematological disorders drug targets·2026

Same author

Transcranial Photobiomodulation Promotes Neurological Resilience in Current Collegiate American Football Players Exposed to Repetitive Head Acceleration Events.

Journal of neurotrauma·2026

Search research articles

Related Experiment Video

Updated: Jun 17, 2025

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

Emerging pharmacological approaches for Huntington's disease.

Kuldeep Singh¹, Divya Jain², Pranshul Sethi³

¹Department of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.

European Journal of Pharmacology

|August 8, 2024

Summary

This summary is machine-generated.

Huntington's disease (HD) treatments are advancing, with new drugs and therapies showing promise. This review explores current pharmacological interventions and future directions for managing HD symptoms and progression.

Keywords:

Huntington's disease Mitochondrial dysfunction Mutant huntingtin protein Neurodegenerative disorders Pharmacological approaches

More Related Videos

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Related Experiment Videos

Last Updated: Jun 17, 2025

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Area of Science:

Neuroscience
Pharmacology
Genetics

Background:

Huntington's disease (HD) is a progressive neurodegenerative disorder with no cure.
Understanding HD pathogenesis involves mutant huntingtin protein, mitochondrial dysfunction, excitotoxicity, and neuro-inflammation.

Purpose of the Study:

To critically appraise the latest developments in pharmacological interventions for Huntington's disease.
To review emerging therapeutic targets and agents, including small molecules, gene-based therapies, and neuroprotective agents.

Main Methods:

Comprehensive literature review of pharmacological approaches for HD.
Analysis of recent clinical trial outcomes for novel HD compounds.
Exploration of drug repurposing strategies for HD treatment.

Main Results:

Emerging pharmacological targets include protein homeostasis, mitochondrial function, neuro-inflammation, and neurotransmitter systems.
Clinical trials show promising results but also present challenges in HD drug development.
Drug repurposing offers a potentially cost-effective avenue for HD treatment.

Conclusions:

Pharmacological interventions for HD are evolving, with multiple strategies showing promise.
Future directions emphasize combination therapies, personalized medicine, and continued drug development.
Despite challenges, advancements offer hope for improved HD symptom management and slowed progression.